Evidence Hub

Efficacy and safety of tadalafil in portopulmonary hypertension

Mitja Jevnikar, Nathan Ebstein, Xavier Jaïs, Athénaïs Boucly, David Montani, Marc J.C. Humbert, Olivier Sitbon, Laurent Savale

2018

33 participants · 4 citations

Abstract

Data on efficacy and safety of tadalafil in portopulmonary hypertension (PoPH) are lacking. The aim of our study was to analyze short- and long-term efficacy and safety of an initial monotherapy with tadalafil in patients with PoPH. All consecutive patients with PoPH initiated with tadalafil were retrospectively analyzed. Clinical and haemodynamic characteristics were assessed at the time of diagnosis (baseline) and during follow-up. Overall survival was analyzed. Thirty-eight patients were analyzed (71% males, mean age 54±11 years). Fourteen patients (37%) were in Child-Pugh (CP) stage A and twenty-four (63%) in CP stage B or C. The mean MELD score was 14±5. Baseline NYHA functional class (FC) distribution was I-II (34%), III (58%) and IV (8%). Baseline 6-min walk distance (6MWD) was 380±120 m, mean pulmonary artery pressure (mPAP) 44±8 mmHg, cardiac index (CI) 3.1±0.9 L/min/m2 and pulmonary vascular resistance (PVR) 6.6±2.8 WU. After a median follow-up of 4 months, 33 patients have been reevaluated. There were significant improvements from baseline in FC (p<0.001), mPAP (-8±8 mmHg, p=0.0001), CI (+0.7±0.3 L/min/m², p=0.005) and PVR (-35±27%, p=0.0001). There was no significant change in 6MWD. Change in PVR was similar irrespective of CP stage. Three patients had significant fluid retention, but no other significant side-effects were observed. During a study follow-up of 18±12 months, 1/14 patients with CP A and 14/24 with CP B-C cirrhosis had died. Overall survival was 73%…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free